title: [Effect of weekly docetaxel in patients with recurrent breast cancer].
abstract: A pilot trial was conducted to assess the tolerability and efficacy of a regimen with weekly docetaxel (TXT) in patients with metastatic breast cancer. The chemotherapy regimen consisted of a 30-minute weekly intravenous infusion of docetaxel (22-33 mg/m2/wk). Each 8-week cycle included 6 weekly treatments, followed by two weeks of rest. Thirteen patients were treated. All patients were evaluable for response: 0 CR (0%), 7 PR (53.8%), 3 NC (23.1%), 3 PD (23.1%). These results are almost the same as those with the administration of TXT (60 mg/m2) q3 wks. Toxicities observed were mild (< or = grade 2) and reversible, and included fatigue, nausea, neutropenia, and alopecia. This preliminary experience suggests a high level of clinical activity and excellent tolerability of the chemotherapy regimen at the given dose and schedule in patients with metastatic breast cancer.
authors.affiliation: Second Dept. of Surgery, Yamanashi Medical University.
authors.forename: K
authors.initials: K
authors.lastname: Koshizuka
authors.forename: M
authors.initials: M
authors.lastname: Serizawa
authors.forename: N
authors.initials: N
authors.lastname: Mouri
authors.forename: S
authors.initials: S
authors.lastname: Muto
authors.forename: K
authors.initials: K
authors.lastname: Takano
authors.forename: Y
authors.initials: Y
authors.lastname: Tada
authors.forename: H
authors.initials: H
authors.lastname: Nakagomi
authors.forename: M
authors.initials: M
authors.lastname: Hada
mesh_terms: D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects; D001943:Breast Neoplasms / Q000188:drug therapy*; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009503:Neutropenia / Q000139:chemically induced; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives; D010865:Pilot Projects; D043823:Taxoids
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel